Developing life-saving therapies for blood cancer patients

Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative and potentially life‑saving therapies for patients with late stage blood cancers and related disorders in need of a transplant, an area of significant unmet medical need.

The Company is currently sponsoring a multi‑center Phase II clinical trial for its lead product ATIR™ and is collaborating with with renowned centers in Europe and North America.

Latest news

March 24, 2014
Kiadis Pharma organizes a satellite symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation
January 29, 2014
Kiadis Pharma initiates collaboration for personalized immunotherapies using ATIR™ with Technische Universität München
December 5, 2013
Kiadis Pharma participates in haploidentical transplantation 2013 Forum
November 18, 2013
Kiadis Pharma provides positive update on its Phase II clinical program with blood cancer treatment ATIR™

Older news items are still available on the News page

 

Fact sheet: a valuable insight into where Kiadis Pharma stands today. It summarizes what the Company's lead product ATIR™ is about, its market potential and the progress that is being made in clinical development. Download fact sheet

Video: five‑year follow‑up of patients with high‑risk malignancies from Phase I/II clinical study confirms long‑term safety and efficacy of ATIR™ over a broad dose range. Download press release

 

Upcoming Conferences



EPIC Biotech Conference
October 2, 2014 - London, United Kingdom